Clinical Trials Directory

Trials / Completed

CompletedNCT00550459

Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients

A Pilot, Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Effects of Titrated Oral Tolvaptan 15, 30, or 60 mg QD on Cognitive and Neurological Function in Elderly Hyponatremic Patients

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
57 (actual)
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
Sex
All
Age
50 Years
Healthy volunteers
Not accepted

Summary

Demonstrate an improvement in the composite scores of validated neurocognitive tests in elderly subjects with chronic sub-clinical (i.e., asymptomatic) hyponatremia.

Detailed description

Subjects will be randomized, with stratification by baseline sodium \<130 or ≥ 130 mEq/L\[mmol/L\] to receive either tolvaptan 15 mg tablet or matching placebo tablet at doses of 15, 30 or 60 mg for 21 days. During this period, fluid restrictions should be loosened or suspended, until the subject's response to therapy can be evaluated, typically over the first few days of therapy. Fluid restriction may be reinstituted at any time in subjects whose sodium fails to improve or worsens with study therapy. A forced-titration up to 60 mg of study drug by day 3 to 7 will be based on the subject's serum sodium Subjects entering the study with a serum sodium concentration less than 130 mEq/L\[mmol/L\] may be fluid restricted if necessary at the discretion of the Investigator. Subjects should be monitored closely during the first 24 hours of treatment for dosing titration. The total dosing duration will be up to 21 days (plus 3 day treatment window). Subjects will return to the clinic on Day 22 (+3 days) for assessments and will complete a follow-up visit on Day 28 (+2 days).

Conditions

Interventions

TypeNameDescription
DRUGTolvaptan15-60 mg oral tablet given once a day for 21 days.
DRUGPlaceboPlacebo tablet given once daily for 21 days

Timeline

Start date
2007-08-01
Primary completion
2009-02-01
Completion
2009-03-01
First posted
2007-10-29
Last updated
2011-04-28
Results posted
2011-04-28

Locations

12 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00550459. Inclusion in this directory is not an endorsement.